Laura E. Zawadzke
Foghorn Therapeutics (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Chromatin Remodeling and Cancer, Multiple Myeloma Research and Treatments, Enzyme Structure and Function, Ubiquitin and proteasome pathways
Most-Cited Works
- → Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1(2012)275 cited
- → Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes(2010)257 cited
- → Existence of two D-alanine:D-alanine ligases in Escherichia coli: cloning and sequencing of the ddlA gene and purification and characterization of the DdlA and DdlB enzymes(1991)132 cited
- → Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma(2016)118 cited
- → Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains(2016)118 cited
- → Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)(2016)111 cited
- → A comparison of the immunogenicity of a pair of enantiomeric proteins(1993)104 cited
- → The structure of a centrosymmetric protein crystal(1993)100 cited
- → Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300(2016)94 cited
- → A racemic protein(1992)94 cited